This is the latest episode of the free DDW narrated podcast, “Innovating now to reinvent the future of drug discovery”. It covers three articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Predictive biomarkers in the age of spatial biology”, “Exploiting the microbiome to drive nature – inspired innovation”, and “Animal research: reinventing the norm”.  In the first article, Ori Zelichov MD, VP Clinical Development at Nucleai, shares insight on the relationship between predictive biomarkers and spatial biology.   In the second article, Dr Sven Sewitz, Director of Biodata Innovation at Eagle Genomics, talks about the need for more effective data and process management to get the best from microbiome data.  In the third article, FRAME Education and Outreach Manager Amy Beale discusses how current legislative and regulatory requirements for animal research could be strengthened to help prevent animal experiments and accelerate change. She also considers the factors influencing the lack of change within animal research.   

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The theme of DDW's news review this week is money. Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and investing in new facilities, as well as government support coming through to boost research in areas of urgent need. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW podcast, “What’s at the forefront of innovation?” It covers three articles written for the for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Can animal genomics help find therapies for human disease?”, “Understanding and innovating in immunology”, and “Cell and gene therapies: Opportunities for innovation”.  In the first article,  Lu Rahman spoke to Ashley Zehnder, CEO of Fauna Bio, a biotech harnessing the power of comparative and functional animal genomics to find better therapies for human disease, including neurologic, metabolic, fibrotic and cardiovascular disorders. In the second article, Chiedzo Mpofu, Vice President, Global Medical Affairs Head, Immunology, at AbbVie, talks to Lu Rahman about our understanding of auto-immune disease and how AbbVie is continuing to innovate in this field.  In the third article, Dr. Deborah Phippard, Chief Scientific Officer of Precision for Medicine and Anshul Mangal, President & General Counsel of Project Farma, share insight on CGTs. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was recently Clinical Trials Day and DDW have reported on the launch of a number of new Phase I trials. In-human studies have been initiated to test treatments for Parkinson’s disease, radioactive contamination, Dravet Syndrome, influenza and inflammatory diseases. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW's Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.  Leveraging historical trial databases has become commonplace in assessing the feasibility of trials in therapeutic areas with a large breadth of clinical development history. In the future, clinical trials are going to come down to the patient level, similar to how therapies are moving toward personalisation based on biomarkers, genetics and more. EHR data also has a key role to play in designing future clinical trials. In this episode, Dr Pace discusses how precision medicine is already starting to influence standards in clinical trial design.